ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine (T-DM1, previously known as trastuzumab-DM1) in HER2-positive metastatic breast cancer (MBC). T-DM1 consists of ImmunoGen's DM1 cancer cell-killing agent attached using the Company's linker to the HER2-targeting antibody, trastuzumab, developed by Genentech, a member of the Roche Group...
No comments:
Post a Comment